CONTEXT AND OBJECTIVE: Patients with beta-thalassemia major (β-TM) experience physical, psychological and social problems that lead to decreased quality of life (QoL). The aim here was to measure health-related QoL and its determinants among patients with β-TM, using the Short Form-36 (SF-36) questionnaire. DESIGN AND SETTING: Cross-sectional study at the Hematology Research Center of Shiraz University of Medical Sciences, in southern Iran. METHODS: One hundred and one patients with β-TM were randomly selected. After the participants' demographics and disease characteristics had been recorded, they were asked to fill out the SF-36 questionnaire. The correlations of clinical and demographic factors with the QoL score were evaluated. RESULTS: There were 44 men and 57 women of mean age 19.52 ± 4.3 years (range 12-38). On two scales, pain (P = 0.041) and emotional role (P = 0.009), the women showed significantly lower scores than the men. Lower income, poor compliance with iron-chelating therapy and presence of comorbidities were significantly correlated with lower SF-36 scores. These factors were also found to be determinants of worse SF-36 scores in multivariate analysis. CONCLUSIONS: We showed that the presence of disease complications, poor compliance with ironchelating therapy and poor economic status were predictors of worse QoL among patients with β-TM. Prevention and proper management of disease-related complications, increased knowledge among patients regarding the importance of managing comorbidities and greater compliance with iron-chelating therapy, along with psychosocial and financial support, could help these patients to cope better with this chronic disease state. 
INTRODUCTION
Beta-thalassemia major (β-TM), also known as Cooley's anemia, is a hemoglobinopathy leading to chronic hemolytic anemia. In individuals with β-TM, there is either complete absence of β-globin gene production or a partial reduction. If patients with β-TM are treated inadequately and inappropriately, it will be a fatal disease. 1 It is a common disease in Mediterranean countries, Southeast Asia, the Indian subcontinent and the Middle East, including Iran. 2, 3 The life expectancy and survival of these patients have increased dramatically over previous decades through introduction of regular blood transfusion therapy and iron-chelating therapies. [4] [5] [6] As well as these patients' survival, their quality of life (QoL) is believed to be lower than that of the normal population because of a variety of issues that these patients encounter during their lives, including the presence of comorbid chronic conditions, treatment components such as periodic regular hospital visits for regular transfusions and painful injections, appearance, absence of sexual development, infertility, inability to raise their own family, disease complications, uncertainties about the future, psychiatric disorders, and difficulties in employment and playing a role within society. 7, 8 Because of these factors, patients with β-TM experience many physical, psychological and social problems that lead to decreased QoL. Culture and education are two independent factors that influence the QoL of patients with β-TM to a great extent. 9 SF-36 is a short-form health survey including 36 questions.
It is a well-recognized, self-administered and user-friendly questionnaire for measuring QoL in general populations as well as in populations with specific conditions. 10 The validity and reliability of the Persian-translated version of this instrument for measuring QoL among thalassemic patients was approved previously by Jafari et al. 11 Information on these patients' QoL can help healthcare providers to draw up essential programs for preventing the consequences of this disease.
OBJECTIVE
In this study, we aimed to measure the QoL of patients with β-TM using SF-36 for the first time in southern Iran. In addition, we wanted to determine predictive factors.
MATERIALS AND METHODS
In this cross-sectional study, a total of 101 patients with SHB β-TM who were being registered at the Hematology Research
Center of Shiraz University of Medical Sciences were randomly enrolled during 2009. All the patients were more than 12 years old and had been transfusion-dependent since before the age of two years. They had been referred to receive regular blood transfusions, to a referral hospital in Shiraz, Southern Iran. All of them were using deferoxamine as iron-chelating therapy, with poor or good compliance. Table 2 shows the SF-36 score results on the eight scales, the two summary statuses for physical and mental health, and total scores for the male and female patients with β-TM.
For the total score and the summaries of physical and mental health, there were no statistically significant differences between the male and female patients. Differences were only seen on two scales (BP and RE), such that the male patients showed significantly higher scores than the female patients (P = 0.041, P = 0.009 respectively). the patients with lower incomes (P < 0.001). Moreover, the patients with good compliance with iron-chelating therapy had higher scores than shown by the patients with poor compliance, in all of these three evaluated scores (P < 0.002). Lack of comorbidities was correlated with having a significantly better physical health score (P = 0.031).
In Table 4 , we have summarized the results from mul- 
DISCUSSION
In this study, the QoL of the patients with β-TM was assessed using SF-36. The SF-36 questionnaire is a well-known selfadministered instrument for assessing QoL in the general population, as well as among patients with various diseases.
The Persian-translated version of this questionnaire has been used to determine reliability and validity in different studies in normal populations, 15, 16 and also among β-thalassemic patients in Iran. 11, 17 We found worse physical health scores for the β-TM patients who had comorbidities, poor compliance with iron-chelating therapy or lower income. Poor compliance with iron-chelating therapy and low income were also found to be related to lower scores for the mental health dimension as well as for total SF-36. Table 4 . Multiple linear regression analysis on determinants of the Short Form-36 (SF-36) scores among patients with betathalassemia major in southern Iran *Statistically significant. DF = degrees of freedom. F = F test. R = correlation coefficient. The independent variables were entered into the multiple linear regression models as follows: comorbidities (1 = yes); compliance with iron-chelating therapy (1 = poor); economic level: high and moderate economic levels were combined together as one group, thus producing two groups: low income and high or moderate income (1 = low income).
In comparison with the results from a SF-36 health survey that was conducted on healthy Iranian individuals, our patients had lower mean scores in all scales except in PF. 15 Similar to our study, Khani et al. 17 reported decreased quality of life of patients with β-TM in North of Iran.
Beta-thalassemia major becomes apparent between the ages of 6 and 24 months. 18 Therefore, homozygotes are involved with this disease since the early months of life. The difference between thalassemic children and their peers gives rise to feelings of anguish, self-scorn and many destructive senses, thereby resulting in decrease life expectancy. 19 The QoL of β-thalassemic patients has increased due to medical advances, improvements in therapeutic methods, safer blood transfusion, new iron chelators and regular treatment methods. 20, 21 Stem cell and bone marrow transplantation and promotion of gene therapy are promising as well. 22 Among the population studied, 68% were not more than 20 years old. We did not find any significant relationship between age and the QoL scores. Sobota et al. 23 investigated QoL in a longitudinal thalassemia cohort aged over 14 years, compared with the norms in the United States, along with the influence of clinical factors. Differing from our results, they showed worse QoL among older patients. They also found lower scores among women. Similarly, in our study, women had lower scores on two scales (BP and RE), although the scores for the two main dimensions and total SF-36 did not show any significant differences between male and female patients. Older age and female gender are factors known to be correlated with lower QoL scores in the general population. 15 Our study showed that 70% of the patients evaluated were at high-school diploma, bachelor's degree or postgraduate degree level. However, educational level did not show any significant association with the SF-36 scores. This is in contrast with the results from Tajvar et al., 24 who found that education was a significant determinant of lower physical health-related quality of life in an elderly population.
Comorbidities were present in 28% of our participants, and these included cardiological disorders, diabetes mellitus, hepatitis B or C, and other related complications. The presence of these associated diseased states was an independent predictive factor for lower physical health summary scores. Consistently with our results, Sobota et al. 23 reported lower scores among thalassemic patients who had higher numbers of these complications.
Particular attention deserves to be paid towards decreasing these co-morbidities and complications through regular periodic follow-up, examination and appropriate management of disease complications in thalassemic patients.
Due to the inevitable associated problems in β-TM, such as cardiological disorders, diabetes mellitus, hepatitis, dependency on periodic blood transfusion and infertility, it is expected that only a few patients may be able to marry. In our study, only 6% of the patients had been married. Nevertheless, marital status had no significant relationship with the SF-36 score.
Patients presenting good compliance with iron-chelat- 27 and diabetic foot ulcers. 28, 29 To promote QoL among thalassemic patients, a variety of factors should be taken into account by health-related policymakers, with special attention to patients presenting any comorbid diseases, poor compliance with iron-chelating therapy and lower socioeconomic status. Psychosocial support should be scheduled for patients and their families in order to prevent mental health issues, behavioral problems and illness complications. 30 Promotion of knowledge about the benefits of therapeutic and prophylactic processes may reduce the level of emotional distress and increase the quality of therapy. 31 Attendance by social workers and psychologists at treatment centers, to provide support and regular peripheral interviews with patients, can improve QoL. Promotion of social knowledge, regular clinical checkups and modern treatment strategies could help to increase the hopes and life expectancy of thalassemic patients. 32 Our study was limited by the lack of a control group, and therefore we were unable to compare the QoL scores of thalassemic patients with similar scores in a normal population. In addition, because this was a patient population in a single referral institution, the results may not be representative of patients in
Iran with this condition.
CONCLUSION
We found that the presence of disease complications, poor compliance with iron-chelating therapy and poor economic status were predictors of worse QoL among patients with β-TM. Prevention and proper management of disease-related complications and greater knowledge among patients regarding the importance of comorbidity management and good compliance with iron-chelating therapy, as well as consideration for these patients' psychosocial and financial support, could be helpful in coping better with this chronic disease state.
